William J He1,2, Changwei Li3, Xuenan Mi2, Mengyao Shi2, Xiaoying Gu4, Lydia A Bazzano2,5, Alexander C Razavi2, Jovia L Nierenberg2, Kirsten Dorans2,5, Hua He2,5, Tanika N Kelly2,5. 1. Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, Maryland. 2. Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana. 3. Department of Epidemiology and Biostatistics, University of Georgia College of Public Health, Athens, Georgia, USA. 4. Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China. 5. Tulane University Translational Sciences Institute, Tulane University, New Orleans, Louisiana, USA.
Abstract
OBJECTIVE: To identify novel and confirm previously reported metabolites associated with SBP, DBP, and hypertension in a biracial sample of Bogalusa Heart Study (BHS) participants. METHODS: We employed untargeted, ultra-high performance liquid chromatography tandem mass spectroscopy metabolomics profiling among 1249 BHS participants (427 African-Americans and 822 whites) with BP and covariable data collected during the 2013 to 2016 visit cycle. A total of 1202 metabolites were tested for associations with continuous and binary BP phenotypes using multiple linear and logistic regression models, respectively, in overall and race-stratified analyses. RESULTS: A total of 24 novel metabolites robustly associated with BP, achieving Bonferroni-corrected P less than 4.16 × 10 in the overall analysis and consistent effect sizes across race groups. The identified metabolites included three amino acid and nucleotide metabolites from histidine, pyrimidine, or tryptophan metabolism sub-pathways, seven cofactor and vitamin or xenobiotic metabolites from the ascorbate and aldarate metabolism, bacterial/fungal, chemical, and food component sub-pathways, 10 lipid metabolites from the eicosanoid, phosphatidylcholine, phosphatidylethanolamine, and sphingolipid metabolism sub-pathways, and four still unnamed metabolites. Six previously described metabolites were robustly confirmed by our study (Bonferroni-corrected P < 4.95 × 10 and consistent effect directions across studies). Furthermore, previously reported metabolites for SBP, DBP, and hypertension demonstrated 5.92-fold, 4.77-fold, and 4.54-fold enrichment for nominally significant signals in the BHS (P = 3.08 × 10, 5.93 × 10, and 2.30 × 10, respectively). CONCLUSION: In aggregate, our study provides new information about potential molecular mechanisms underlying BP regulation. We also demonstrate reproducibility of findings across studies despite differences in study populations and metabolite profiling methods.
OBJECTIVE: To identify novel and confirm previously reported metabolites associated with SBP, DBP, and hypertension in a biracial sample of Bogalusa Heart Study (BHS) participants. METHODS: We employed untargeted, ultra-high performance liquid chromatography tandem mass spectroscopy metabolomics profiling among 1249 BHS participants (427 African-Americans and 822 whites) with BP and covariable data collected during the 2013 to 2016 visit cycle. A total of 1202 metabolites were tested for associations with continuous and binary BP phenotypes using multiple linear and logistic regression models, respectively, in overall and race-stratified analyses. RESULTS: A total of 24 novel metabolites robustly associated with BP, achieving Bonferroni-corrected P less than 4.16 × 10 in the overall analysis and consistent effect sizes across race groups. The identified metabolites included three amino acid and nucleotide metabolites from histidine, pyrimidine, or tryptophan metabolism sub-pathways, seven cofactor and vitamin or xenobiotic metabolites from the ascorbate and aldarate metabolism, bacterial/fungal, chemical, and food component sub-pathways, 10 lipid metabolites from the eicosanoid, phosphatidylcholine, phosphatidylethanolamine, and sphingolipid metabolism sub-pathways, and four still unnamed metabolites. Six previously described metabolites were robustly confirmed by our study (Bonferroni-corrected P < 4.95 × 10 and consistent effect directions across studies). Furthermore, previously reported metabolites for SBP, DBP, and hypertension demonstrated 5.92-fold, 4.77-fold, and 4.54-fold enrichment for nominally significant signals in the BHS (P = 3.08 × 10, 5.93 × 10, and 2.30 × 10, respectively). CONCLUSION: In aggregate, our study provides new information about potential molecular mechanisms underlying BP regulation. We also demonstrate reproducibility of findings across studies despite differences in study populations and metabolite profiling methods.
Authors: Shengyuan Luo; Josef Coresh; Adrienne Tin; Casey M Rebholz; Lawrence J Appel; Jingsha Chen; Ramachandran S Vasan; Amanda H Anderson; Harold I Feldman; Paul L Kimmel; Sushrut S Waikar; Anna Köttgen; Anne M Evans; Andrew S Levey; Lesley A Inker; Mark J Sarnak; Morgan Erika Grams Journal: Clin J Am Soc Nephrol Date: 2019-02-07 Impact factor: 8.237
Authors: Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He Journal: Lancet Date: 2005 Jan 15-21 Impact factor: 79.321
Authors: Yan Zheng; Bing Yu; Danny Alexander; Thomas H Mosley; Gerardo Heiss; Jennifer A Nettleton; Eric Boerwinkle Journal: Hypertension Date: 2013-06-17 Impact factor: 10.190
Authors: Elaine Holmes; Ruey Leng Loo; Jeremiah Stamler; Magda Bictash; Ivan K S Yap; Queenie Chan; Tim Ebbels; Maria De Iorio; Ian J Brown; Kirill A Veselkov; Martha L Daviglus; Hugo Kesteloot; Hirotsugu Ueshima; Liancheng Zhao; Jeremy K Nicholson; Paul Elliott Journal: Nature Date: 2008-04-20 Impact factor: 49.962
Authors: Eugene P Rhee; Sushrut S Waikar; Casey M Rebholz; Zihe Zheng; Regis Perichon; Clary B Clish; Anne M Evans; Julian Avila; Michelle R Denburg; Amanda Hyre Anderson; Ramachandran S Vasan; Harold I Feldman; Paul L Kimmel; Josef Coresh Journal: Clin J Am Soc Nephrol Date: 2018-12-20 Impact factor: 10.614
Authors: Joonatan Palmu; Emmi Tikkanen; Aki S Havulinna; Erkki Vartiainen; Annamari Lundqvist; Matti O Ruuskanen; Markus Perola; Mika Ala-Korpela; Pekka Jousilahti; Peter Würtz; Veikko Salomaa; Leo Lahti; Teemu Niiranen Journal: J Hypertens Date: 2022-03-01 Impact factor: 4.844
Authors: Jiahong Sun; Min Zhao; Liu Yang; Xue Liu; Lucia Pacifico; Claudio Chiesa; Bo Xi Journal: Int J Hypertens Date: 2021-08-24 Impact factor: 2.420